BridgeBio Pharma Inc. [NASDAQ: BBIO] loss -0.49% on the last trading session, reaching $40.74 price per share at the time. The company report on November 19, 2021 that BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types.
– The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
– BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies.
BridgeBio Pharma Inc. represents 146.66 million in outstanding shares, while the company has a total market value of $6.31 billion with the latest information. BBIO stock price has been found in the range of $40.07 to $40.995.
If compared to the average trading volume of 800.60K shares, BBIO reached a trading volume of 882746 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BridgeBio Pharma Inc. [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $81.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 10, 2021. While these analysts kept the previous recommendation, UBS raised their target price to Buy. The new note on the price target was released on May 21, 2021, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise from $83 to $91, while Goldman kept a Buy rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 1.97, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 110.72.
Trading performance analysis for BBIO stock
BridgeBio Pharma Inc. [BBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.63. With this latest performance, BBIO shares dropped by -16.99% in over the last four-week period, additionally sinking by -29.75% over the last 6 months – not to mention a drop of -13.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 28.98, with the RSI for the last a single of trading hit 21.27, and the three-weeks RSI is set at 33.89 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 47.90, while it was recorded at 41.97 for the last single week of trading, and 55.54 for the last 200 days.
BridgeBio Pharma Inc. [BBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -5751.99. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -5439.74.
Return on Total Capital for BBIO is now -80.46, given the latest momentum, and Return on Invested Capital for the company is -85.58. Return on Equity for this stock declined to -192.44, with Return on Assets sitting at -67.21. When it comes to the capital structure of this company, BridgeBio Pharma Inc. [BBIO] has a Total Debt to Total Equity ratio set at 856.19. Additionally, BBIO Total Debt to Total Capital is recorded at 89.54, with Total Debt to Total Assets ending up at 70.47. Long-Term Debt to Equity for the company is recorded at 847.12, with the Long-Term Debt to Total Capital now at 88.59.
Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,165,517 per employee.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
BridgeBio Pharma Inc. [BBIO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BridgeBio Pharma Inc. posted -0.98/share EPS, while the average EPS was predicted by analysts to be reported at -0.92/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -6.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBIO.
An analysis of insider ownership at BridgeBio Pharma Inc. [BBIO]
There are presently around $5,714 million, or 93.60% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31,060,971, which is approximately 0% of the company’s market cap and around 3.40% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $1.08 billion in BBIO stocks shares; and BLACKROCK INC., currently with $413.16 million in BBIO stock with ownership of nearly 6.747% of the company’s market capitalization.
Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 117 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 5,701,876 shares. Additionally, 81 investors decreased positions by around 7,806,976 shares, while 36 investors held positions by with 126,751,529 shares. The mentioned changes placed institutional holdings at 140,260,381 shares, according to the latest SEC report filing. BBIO stock had 32 new institutional investments in for a total of 1,819,581 shares, while 19 institutional investors sold positions of 2,934,935 shares during the same period.